SCHEMBL19259050

SCHEMBL19259050

Cc1noc(COCc2ccc(N)cc2)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.53
MAPT P10636 1/20 0.53
CYP2C9 P11712 1/20 0.53
CYP2C19 P33261 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ACHE P22303 1/20 0.46
HTR1A P08908 2/20 0.40
HTR2C P28335 2/20 0.40
GSTP1 P09211 5/20 0.37
ALOX5AP P20292 1/20 0.35
FEN1 P39748 1/20 0.35
SLC6A3 Q01959 2/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35
RAB9A P51151 1/20 0.35
MAPK10 P53779 1/20 0.35
HIF1A Q16665 1/20 0.34
MCHR1 Q99705 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19482556 0.82 MAPT (0.48) SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL655929 0.79 MAPT (0.84) SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL4007043 0.79 ACHE (0.50) SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL19259049 0.79 MAPT (0.47) SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL234606 0.73 ALDH1A1 (0.55) SMN1; SMN2MAPTHSD17B10RAB9AHIF1A
SCHEMBL15492423 0.72 MAPT (0.56) SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10
SCHEMBL26788164 0.72 ACHE (0.59) SMN1; SMN2MAPTACHENPC1RAB9A
SCHEMBL13141019 0.70
SCHEMBL22593402 0.70
SCHEMBL4002722 0.69 MAPT (0.65) SMN1; SMN2MAPTCYP2C9CYP2C19HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904457-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY RIGEL PHARMACEUTICALS INC (US) 2017-09-06 EP disclosed
US-9732073-B2 Compositions and methods for inhibition of the JAK pathway RIGEL PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed